YEDA’s BUSINESS CLUB

Welcome to

2016

2

JUNE2015

3 YEARS COLLABORATION FOR DETERMINING CONSUMER UNDERSTANDING OF VARIOUS STIMULATIONS.

UNILEVER – SOBEL

3

JUNE2015

A NEW COMPANY AIMING TO DEVELOP BACTERIOPHAGE-BASED THERAPIES FOR THE TREATMENT AND PREVENTION OF DISEASES STEMMING FROM THE MICROBIOME.

MBCURE

4

JULY2015

RSeT™ is a defined medium that allows researchers to revert human primed pluripotent stem cells to a naive-like state. RSeT™ also enables researchers to culture human naive-like pluripotent stem cells long-term and supports this rapidly expanding field of human pluripotent stem cell (hPSC) research.

STEMCELL

5

NOVEMBER2015

PERSONALIZED NUTRITION AND ACTIONABLE INSIGHTS THAT ALLOW YOU TO LIVE HEALTHIER AND MAINTAIN NORMAL BLOOD SUGAR LEVELS.

DAYTWO

BASED ON THE WORK OF PROF. SEGAL AND PROF. ELINAV

NOVEMBER2015 cont’d

A collaboration agreement allowing easy access to Korean companies to WIS technologies.

6

KORIL-RDF

ImmunArray launches a new blood test for lupus which is being rolled out nationally. This will provide a wider group of rheumatologists with a simple, accurate means for ruling out whether a patient is suffering from the chronic, autoimmune disease that affects 1.5 million Americans, mostly women between the ages of 18 and 60.

ImmunArray

7

NOVEMBER2015 cont’d

AB2 Bio Ltd. achieved a medical breakthrough in the treatment of systemic inflammation. Drug candidate effective in treating a baby girl carrying a newly identified, potentially fatal, genetic mutation causing severe systemic inflammation.

AB2 BIO

I L 1 8 B D WA S D I S C O V E R E D B Y D R . D A N I E L A N O V I K

8

DECEMBER2015

WEIZMANN INSTITUTE DRUG, TOOKAD® SOLUBLE, APPROVED FOR PROSTATE CANCER THERAPY IN MEXICO and ISRAEL

TOOKAD® SOLUBLE

A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (France) has been approved for the treatment of early-stage prostate cancer by Mexico’s Secretariat of Health. The approval comes in the wake of the recent successful completion of a Phase III clinical trial on more than 400 patients at 55 medical centers in 11 European countries, as well as a confirmatory, Phase III study on 80 patients in Mexico.

9

DECEMBER2015 cont’

KADIMASTEM REACHED AGREEMENTS WITH THE FDA REGARDING THE FRAMEWORK OF THE CLINICAL TRIALS IN HUMANS FOR THE TREATMENT OF ALS.

KADIMASTEM

10

DECEMBER2015 cont’d

Sun Pharmaceutical Industries Ltd. entered into a tripartite research and option agreement with Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma.

SUNPHARMA

11

FEBRUARY2016

AWARDED FOR ITS "INNOVATION POTENTIAL" AT THE INTERNATIONAL QUALITY INNOVATION OF THE YEAR CEREMONY IN ESTONIA.

NEWCO2FUELS (NCF)

FEBRUARY2016

MERCK AND WEIZMANN INSTITUTE SIGN NEW FRAMEWORK AGREEMENT ON RESEARCH COLLABORATION

12

MERCK-WEIZMANN

AS PART OF THE NEW FRAMEWORK AGREEMENT MERCK WILL FUND EACH OF THE TWO RESEARCH AREAS WITH UP TO € 1 MILLION PER YEAR OVER A 3-YEAR PERIOD.

13

MARCH2016

A NEW SPINOUT COMPANY RONDIX WAS BORN.

RONDINX

BASED ON THE WORK OF PROF. SEGAL AND PROF. ELINAV

NEXT GENERATION SEQUENCING AND ANALYZING OF THE MICROBIOME.

14

MARCH2016

FROM A SINGLE PATENTTO THREE DRUGS

$1,081 MILLIONErbitux® Merck and Eli Lillymetastatic colorectal cancer

$500 M (EST 2016)Portrazza® Eli LillyLung cancer

$359 MILLIONVectibix® AMGENColorectal cancer

Prof. Sela and colleagues discovered that EGFR-inhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy

The three EGFR blockers are saving the lives of hundreds of thousands of cancer patients all over the world

EGFR BLOCKERS

15

MARCH2016

NOVEL ANTIBODIES BASED THERAPIES TARGETING MMP 9.

MABTRIX

BASED ON THE WORK OF PROF. IRIT SAGI

Core technology is based on a molecular structure and biophysics platform which enables to identify and design highly potent and extremely selective monoclonal antibody against a physiological conformation of target molecule

16

THANK YOU !

17